1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

JP Morgan: Brandicourt Signals M&A Interest To Boost Sanofi's Growth

 
• By Sukaina Virji

Olivier Brandicourt had a lot to say at his first JP Morgan as Sanofi CEO. With plans to deliver on an "underappreciated" vaccine portfolio, ambitions to "double revenues" from the multiple sclerosis franchise, and a "rebuilding" of the oncology pipeline through M&A, Scrip is enjoying Brandicourt's energy.

Olivier Brandicourt had a lot to say at his first JP Morgan as Sanofi CEO. With plans to deliver on an "underappreciated" vaccine portfolio, ambitions to "double revenues" from the multiple sclerosis franchise, and a "rebuilding" of the oncology pipeline through M&A, Scrip is enjoying Brandicourt's energy.

The CEO had already said much of what he discussed at the 34th annual JP Morgan Healthcare Conference on Jan. 12 – including his plans for Sanofi's ailing diabetes franchise – when he announced the asset swap with Boehringer Ingelheim in December, and at Sanofi's investor day in November, and when Brandicourt revealed his

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.